NCT05727072View on ClinicalTrials.gov

A Study of LY3848575 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

February 19, 2024

Study Completion Date

February 19, 2024

Conditions

Healthy

Interventions

DRUG

LY3848575

Administered IV.

DRUG

LY3848575

Administered SC.

DRUG

Placebo

Administered IV.

DRUG

Placebo

Administered SC.

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY